FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Keyword: genetic testing
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Study : Promising early results for people with DNA mismatch repair deficient rectal cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Most relevant for: People with rectal cancer with high mutational burden or mismatch repair problems including people with Lynch syndrome.
A small research study tested the usefulness of the immunotherapy drug dostarlimab for treating locally advanced rectal cancer with a biomarker known as “dMMR” (DNA mismatch repair deficient). None of the participants had evidence of cancer six months later; some remained cancer free for up to 25 months). Many participants had Lynch syndrome. The remarkable response to this treatment may allow people with this particular subtype of rectal cancer to avoid potentially life-changing rectal surgery. (Posted 11/14/22) Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : Prostate cancer screening may benefit people with Lynch syndrome
Relevance: High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People with Lynch syndrome
Initial results from the IMPACT trial show that PSA testing to screen for prostate cancer in people with Lynch syndrome can detect aggressive early prostate cancers. These findings support the use of PSA screening in men with Lynch syndrome, particularly men with an inherited mutation in an MSH2 or MSH6 gene. (Posted 11/10/22)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Resistant starch may help prevent some cancers in people with Lynch syndrome
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with Lynch syndrome and people with a personal and/or family history that suggests Lynch syndrome
This study looked at whether a type of nutrient known as resistant starch could lower the risk of cancers in people with Lynch Syndrome. Researchers found that resistant starch can reduce the risk of non-colorectal cancers but not colorectal cancer. (Posted 10/17/22)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Study : Teens and young adults respond well to learning about familial cancer risk
Relevance: Medium-High
Strength of Science: Medium-High
Most relevant for: Mothers who have had genetic testing for BRCA1 or BRCA2 whether or not they have been diagnosed with breast or ovarian cancer
Little is known about how awareness of hereditary cancer in a high-risk family affects the quality of life of teens and young adults. This study looked at the lifestyle choices, cancer awareness and quality of life of adolescents and young adults whose mothers had undergone testing for a BRCA mutation. (Posted 10/11/2022) Este artículo está disponible en español.
Read MoreRelevance: High
Quality of Writing: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsArticle : Chris Evert's ovarian cancer diagnosis highlights the importance of genetic counseling and testing
Relevance: High
Quality of Writing: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with genetic test result called a VUS
Tennis star Chris Evert shared her story about a change in her sister's genetic test results that led Ms. Evert to have genetic testing and her decision to have her ovaries removed to lower her cancer risk. Ovarian cancer was found at the time of Ms. Evert’s surgery, but fortunately, it was caught early. Her story highlights the importance of genetic counseling, testing and post-testing follow-up with experts. (Posted 2/8/22). Este artículo está disponible en español.
Read MoreRelevance: Medium
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Multiple sclerosis may affect breast and colorectal cancer survival
Relevance: Medium
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: People with multiple sclerosis who are diagnosed with cancer
People with multiple sclerosis (MS) have lower overall survival after a breast or colorectal cancer diagnosis compared to people diagnosed with these cancers who do not have multiple sclerosis. Survival differed by cancer type. (posted 12/10/21)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : Mutations in BRCA1 or BRCA2 may increase risk for endometrial cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with BRCA1 or BRCA2 mutations
A Dutch study added further evidence that women with a BRCA1 mutation may have an elevated risk for endometrial cancer. The study found that the endometrial cancer in women with either a BRCA1 or BRCA2 mutation was more likely to be an aggressive form of cancer associated with a poor outcomes. (posted 11/30/21)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Genetic testing for inherited mutations may be helpful for all people with advanced or metastatic cancer
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: people with metastatic or recurrent cancer
In a study of nearly 12,000 cancer patients with a variety of cancers, eight percent of participants with metastatic cancer had an inherited mutation in a cancer gene that qualified them for a targeted treatment approved by the FDA or for participation in a clinical trial. The majority of people with metastatic cancer were unaware that they had an inherited mutation, and had not receive gene-directed treatment to which their tumor may have responded. The study authors suggest that genetic testing for inherited mutations may be warranted for all patients with advanced or metastatic cancer. (posted 9/30/21)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Frequency of inherited mutations linked to breast cancer are similar in Black and white women
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: Non-Hispanic Black and white women with breast cancer
The CARRIERS study looked at the rate of inherited mutations in women with and without breast cancer. In an extension of the CARRIERS study, researchers found no difference in the frequency of inherited mutations in breast cancer genes among Black and white women with breast cancer. A few individual genes differed in frequency: BRCA2 and PALB2 mutations were seen more often in Black women, while CHEK2 mutations were seen less often. Researchers concluded that race should not be used to determine who is referred for genetic testing. (posted 8/13/21)
Este artículo está disponible en español.
Read MoreArticle : Overview of pancreatic cancer treatment options
Most relevant for: People with pancreatic cancer
This review looks at current strategies for pancreatic cancer care and potential future therapies. (posted 7/28/21)
Este artículo está disponible en español.
Read More